{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:34:05Z","timestamp":1761129245575},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:00:00Z","timestamp":1436227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/nrrheum.2015.94","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T05:53:30Z","timestamp":1436248410000},"page":"506-507","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Why compare the effectiveness of suboptimal gout management?"],"prefix":"10.1038","volume":"11","author":[{"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"BFnrrheum201594_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna, D.  et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthri tis Care Res. (Hoboken) 64, 1431\u20131446 (2012).","journal-title":"Arthri tis Care Res. (Hoboken)"},{"key":"BFnrrheum201594_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","volume":"17","author":"JA Singh","year":"2015","unstructured":"Singh, J. A., Akhras, K. S. & Shiozawa, A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res. Ther. 17, 120 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201594_CR3","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker, M. A.  et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450\u20132461 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201594_CR4","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker, M. A.  et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 12, R63 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201594_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr.","year":"2008","unstructured":"Schumacher, H. R. Jr.  et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540\u20131548 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201594_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees, F., Jenkins, W. & Doherty, M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann. Rheum. Dis. 72, 826\u2013830 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201594_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp, L. K.  et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 63, 412\u2013421 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201594_CR8","doi-asserted-by":"publisher","first-page":"e003627","DOI":"10.1136\/bmjopen-2013-003627","volume":"4","author":"RD Goldfien","year":"2014","unstructured":"Goldfien, R. D.  et al. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open 4, e003627 (2014).","journal-title":"BMJ Open"},{"key":"BFnrrheum201594_CR9","unstructured":"Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress (US Department of Health and Human Services, Washington DC, 2009)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2015.94.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2015.94","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2015.94.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:38:21Z","timestamp":1684471101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2015.94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFnrrheum201594"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2015.94","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,7]]},"assertion":[{"value":"7 July 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.D. declares she has received consulting fees, speaker fees or grants from Ardea, AstraZeneca, Cymabay, Fonterra, Menarini, Metabolex, Pfizer, Savient, Takeda and Teijin. L.K.S. declares she has received consulting fees from AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}